Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

80 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer.
Friedrich MG, Erbersdobler A, Schwaibold H, Conrad S, Huland E, Huland H. Friedrich MG, et al. Among authors: huland e, huland h. J Urol. 2000 Mar;163(3):1039-42. J Urol. 2000. PMID: 10688045 Clinical Trial.
Distribution of 486P 3/12 antigen, ABO(H) blood group antigen and T antigen in cystectomy specimens from patients with stage T2 transitional cell carcinoma of the bladder.
Heinzer H, Huland E, Mönk M, Huland H. Heinzer H, et al. Among authors: huland e, huland h. J Urol. 1992 Sep;148(3):802-5. doi: 10.1016/s0022-5347(17)36726-5. J Urol. 1992. PMID: 1512830
Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells.
Huland E, Huland H. Huland E, et al. Among authors: huland h. J Cancer Res Clin Oncol. 1992;118(6):463-7. doi: 10.1007/BF01629431. J Cancer Res Clin Oncol. 1992. PMID: 1618895
We recently described a new local IL-2 approach to therapy for advanced bladder carcinoma that allows, for the first time, high-dose continuous administration of natural interleukin-2 (nIL-2) at the tumor site without side-effects [Huland and Huland (1989) Cancer Re …
We recently described a new local IL-2 approach to therapy for advanced bladder carcinoma that allows, for the first time, high-dose continu …
Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder.
Huland E, Huland H, Meier T, Baricordi O, Fradet Y, Grossman HB, Hodges GM, Messing EM, Schmitz-Draeger BJ. Huland E, et al. Among authors: huland h. J Urol. 1991 Dec;146(6):1631-6. doi: 10.1016/s0022-5347(17)38202-2. J Urol. 1991. PMID: 1719252
Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma.
Huland E, Huland H, Heinzer H. Huland E, et al. Among authors: huland h. J Urol. 1992 Feb;147(2):344-8. doi: 10.1016/s0022-5347(17)37233-6. J Urol. 1992. PMID: 1732590
Sensitivity of urinary quantitative immunocytology with monoclonal antibody 486 P3/12 in 241 unselected patients with bladder carcinoma.
Klän R, Huland E, Baisch H, Huland H. Klän R, et al. Among authors: huland e, huland h. J Urol. 1991 Mar;145(3):495-7. doi: 10.1016/s0022-5347(17)38378-7. J Urol. 1991. PMID: 1997697
Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients.
Huland H, Klöppel G, Feddersen I, Otto U, Brachmann W, Hubmann H, Kaufmann J, Knipper W, Lantzius-Beninga F, Huland E. Huland H, et al. Among authors: huland e. J Urol. 1990 Jul;144(1):68-71; discussion 71-2. doi: 10.1016/s0022-5347(17)39368-0. J Urol. 1990. PMID: 2113590 Clinical Trial.
Immunocytology as a possible marker to identify patients who require prophylaxis.
Huland H, Schneider A, Huland E, Arndt R. Huland H, et al. Among authors: huland e. Prog Clin Biol Res. 1990;350:35-9. Prog Clin Biol Res. 1990. PMID: 2117288 Clinical Trial. No abstract available.
Quantitative immunocytology in the management of patients with superficial bladder carcinoma. I. A marker to identify patients who do not require prophylaxis.
Huland E, Huland H, Schneider AW. Huland E, et al. Among authors: huland h. J Urol. 1990 Sep;144(3):637-9; discussion 639-40. doi: 10.1016/s0022-5347(17)39543-5. J Urol. 1990. PMID: 2388319
Monoclonal antibody 486 P 3/12: a valuable bladder carcinoma marker for immunocytology.
Huland H, Arndt R, Huland E, Loening T, Steffens M. Huland H, et al. Among authors: huland e. J Urol. 1987 Apr;137(4):654-9. doi: 10.1016/s0022-5347(17)44166-8. J Urol. 1987. PMID: 2435926
80 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback